Active Filter(s):
Details:
PRAX-562 is a first selective persistent sodium current blocker. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE.
Lead Product(s): PRAX-562
Therapeutic Area: Genetic Disease Product Name: PRAX-562
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
PRX-P4-003 is a new chemical entity (NCE) that incorporates an active isomer of fencamfamine, a well-tolerated Schedule IV stimulant. Fencamfamine has a long-established clinical profile following decades of therapeutic use in Europe and other countries.
Lead Product(s): PRX-P4-003
Therapeutic Area: Psychiatry/Psychology Product Name: PRX-P4-003
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020